- Clinical data published in the international academic journal ‘Clinical Cancer Research’
- ABL111, nivolumab, and chemotherapy triple combination therapy are in development as first-line treatment for gastric cancer
[by Kang, In Hyo] ABL Bio, a company specializing in dual antibody therapeutics, announced on July 2 that its partner company I-Mab has published clinical data on the monotherapy of ‘ABL111 (givastomic),’ a bispecific antibody targeting Claudin18.2 and 4-1BB, in the international academic journal Clinical Cancer Research (CCR).
CCR is a leading peer-reviewed journal in the field of clinical oncology, published by the American Association for Cancer Research (AACR). The recently published article presents encouraging efficacy and safety data from a Phase 1 clinical trial of ABL111 monotherapy in patients with 피망 바카라.2-positive gastric cancer.
The Phase 1 clinical data for ABL111 monotherapy had previously been presented in poster format at the European Society for Medical Oncology (ESMO) annual meetings in 2023 and 2024. The clinical trial enrolled a total of 75 patients with solid tumors, including gastric cancer, among whom 43 had advanced or metastatic gastroesophageal cancer expressing 피망 바카라.2.
Data analysis revealed that 7 out of the 43 patients with 피망 바카라.2-positive achieved a partial response (PR), with an objective response rate (ORR) of 16% (7/43) for ABL111 monotherapy. Following the data cutoff presented at ESMO 2024, 2 additional patients were enrolled, with 1 achieving PR, thereby increasing the ORR to 18% (8/45).
The disease control rate (DCR) was 49% (21 out of 43 patients), including 14 patients who achieved stable disease (SD). Most adverse reactions were reported as mild, classified as grade 1 to 2. Notably, the 피망 바카라.2 expression levels in patients who responded to ABL111 monotherapy ranged from 11% to 100%, indicating that the treatment may demonstrate therapeutic efficacy even in patients with relatively low 피망 바카라.2 expression, according to the company.
“We are pleased to publish the clinical data of ABL111 monotherapy as the first paper in the prestigious international academic journal CCR,” said Lee Sang-hoon, CEO of ABL Bio. “Moving forward, we will make every effort to successfully advance global clinical trials of ABL111 through close collaboration with I-Mab, and to produce meaningful results in combination therapy clinical trials that may offer new treatment options for patients with gastric cancer,” he added.
ABL111 is a bispecific antibody targeting 피망 바카라.2-positive tumors, with a mechanism of action that enables selective activation of T cells via the 4-1BB pathway specifically in the tumor microenvironment where 피망 바카라.2 is expressed. The treatment is currently in Phase 1b clinical trial as part of a triple combination therapy with the immune checkpoint inhibitor nivolumab and chemotherapy, with the goal of developing it as a ‘first-line treatment’ for patients with gastric cancer. In the previous Phase 1 clinical trial, ABL111 monotherapy demonstrated strong antitumor activity driven by the close interaction between 피망 바카라.2 and 4-1BB, while mitigating the toxicity commonly seen in conventional 4-1BB-targeting antibodies.